Want to join the conversation?
In addition to AKN-083, $AGN's Akarna acquisition also includes a portfolio of some development-stage farnesoid X receptor compounds. AKN-083 is complementary to Cenicriviroc and Evogliptin, the development compounds of Tobira Therapeutics the acquisition of which was also announced on Sept. 20.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.